National Kidney Foundation and RenalytixAI Partner to Improve Early Stage Kidney Disease
December 03, 2020
December 03, 2020
NEW YORK, Dec. 3 -- The National Kidney Foundation issued the following news release on Dec. 2:
The National Kidney Foundation (NKF) announced today a partnership with Renalytix AI (NASDAQ:RNLX) to improve kidney disease diagnosis and assessment in the earliest stage of the disease that will ultimately guide clinical interventions and treatments for improved outcomes and quality of life.
Kidney disease affects an estimated 37 million adults in the U.S. and can lead to l . . .
The National Kidney Foundation (NKF) announced today a partnership with Renalytix AI (NASDAQ:RNLX) to improve kidney disease diagnosis and assessment in the earliest stage of the disease that will ultimately guide clinical interventions and treatments for improved outcomes and quality of life.
Kidney disease affects an estimated 37 million adults in the U.S. and can lead to l . . .